Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT00866723) enrolled 5 participants, all of whom received a medicine called bevacizumab. The trial was measuring two things: first, how many participants showed a meaningful reduction in their cancer during treatment (called the "clinical response rate"); and second, how many participants had no sign of their cancer getting worse by the 18-week mark (called the "clinical benefit response rate"). Notably, the reported data shows that none of the 5 participants completed the study, though the reasons for this are not detailed in the submitted results. The reported data shows that 0.20 (or 1 in 5 participants) met the criteria for a clinical response — meaning their tumour shrank by a meaningful amount, or their CA-125 blood marker (a marker sometimes associated with certain cancers) dropped by at least half, depending on how their disease was being tracked. For the second measure, the reported data shows that 0.80 (or 4 in 5 participants) had no recorded sign of their disease getting worse by 18 weeks. It is worth noting that because no participants completed the study, these figures come from a very small group, and the data as submitted does not explain the circumstances around participants not completing. Because only 5 people took part and none finished the study, the reported numbers are based on a very limited group. The data was not reported in a way that allows any broader conclusions to be drawn from these figures alone. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Ovarian Cancer Trial, Terminated
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with epithelial ovarian cancer, primary peritoneal serous cancer, papillary serous endometrial cancer, or fallopian tube cancer, confirmed by a lab test
- Your cancer responded well to a first round of platinum-based chemotherapy followed by bevacizumab maintenance treatment, and you remained stable (shown by normal physical exam, normal CA125 blood test, and normal CT scan)
- Your cancer has come back at least 3 months after finishing bevacizumab maintenance, either showing new measurable tumours (none larger than 3 centimetres) on a scan, or a significantly raised CA125 blood test on two separate occasions
- You are able to carry out basic daily activities, with little to no limitation from your illness (confirm with trial site)
- You are 18 years of age or older
- You are expected to live for at least 6 months
- Your organ function (such as kidney, liver, and bone marrow) is within acceptable levels as set out by the trial
- Any side effects from previous chemotherapy or hormonal therapy have mostly or fully cleared up before restarting bevacizumab
- You have not received any chemotherapy or targeted biological treatment for your cancer returning
- You may have previously received hormone-based therapy for your cancer
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have already received chemotherapy or biological therapy to treat your cancer after it came back
- You have a known cancer spread to the brain, unless it has already been treated (confirm with trial site)
- You are pregnant or breastfeeding
- You have uncontrolled serious health conditions such as high blood pressure, an active infection, heart failure, unstable chest pain, an irregular heartbeat, or a mental health or personal situation that would make it difficult to follow the trial requirements
- You have had a major operation, open biopsy, or serious injury in the 28 days before starting the trial, or you are expected to need major surgery during the trial
- You have had a minor surgical procedure (other than having a vascular device inserted) within 7 days before joining the trial
- You have a history of an abnormal opening between the abdomen and another organ (fistula), a hole in the bowel, an abscess inside the abdomen, or scan evidence of a bowel blockage or thickening
- You have symptoms of a bowel blockage, or you need fluids or nutrition delivered directly into your veins
- You have had another active cancer in the last 3 years, except for certain skin cancers or very early-stage breast or cervical cancer
- You have uncontrolled high blood pressure (if you have high blood pressure, it must be managed to below 150/90 before starting treatment)
- You have a significant amount of protein in your urine at the time of screening
- You have dementia or a serious mental condition that would prevent you from understanding and agreeing to take part in the trial
- You are currently taking blood-thinning medication — this is not automatically a reason to be excluded, but certain higher-risk patients will need to be reviewed by the lead doctor (confirm with trial site)
- You have any active bleeding
- You have a serious wound, ulcer, or bone fracture that is not healing
- You have a history of a severe high blood pressure crisis or high-blood-pressure-related brain swelling
- You have moderate or severe heart failure (confirm with trial site)
- You have had a heart attack or severe chest pain within the last 6 months
- You have had a stroke or a temporary stroke-like episode within the last 6 months
- You have had a significant blood vessel problem within the last 6 months
- You have coughed up blood within the last month
- You have any measurable tumour that is larger than 3 centimetres
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Clinical Response Rate; Clinical Benefit Response Rate
Other options
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.